胃息肉 中国就医指南

Gastric polyps are localized, benign mucosal protrusions arising from the stomach lining. They are typically discovered incidentally during upper gastrointestinal endoscopy performed for unrelated symptoms such as dyspepsia, anemia, or surveillance. While most gastric polyps are asymptomatic and non-neoplastic, their clinical significance lies in their heterogeneous histopathology—primarily classified as hyperplastic polyps (60–80%), fundic gland polyps (10–30%), and adenomatous polyps (<10%). Adenomatous polyps carry the highest malignant potential, with risk of progression to gastric adenocarcinoma increasing with size (>2 cm), dysplasia grade, and presence of intestinal metaplasia. Pathogenesis varies by type: hyperplastic polyps are strongly associated with chronic atrophic gastritis and Helicobacter pylori infection, leading to mucosal injury and regenerative hyperplasia; fundic gland polyps are often linked to long-term proton pump inhibitor (PPI) use or familial adenomatous polyposis (FAP); adenomatous polyps arise from neoplastic transformation of gastric epithelium, frequently in the context of chronic inflammation, bile reflux, or genetic predisposition. Epidemiologically, gastric polyps are detected in 1–6% of routine upper endoscopies in adults, with prevalence rising sharply after age 50. Hyperplastic polyps predominate in older women and individuals with H. pylori-related gastritis, while fundic gland polyps are more common in middle-aged women on chronic PPI therapy. Risk factors include persistent H. pylori infection, autoimmune gastritis, long-term PPI use (>1 year), smoking, high-salt diet, and genetic syndromes such as FAP or Lynch syndrome. Although most patients remain asymptomatic, larger or multiple polyps may cause occult gastrointestinal bleeding (leading to iron-deficiency anemia), epigastric discomfort, nausea, or, rarely, gastric outlet obstruction. Quality of life impact is generally low for small, non-dysplastic polyps under surveillance; however, patients face psychological burden from cancer anxiety, repeated endoscopic monitoring, dietary restrictions, and medication adjustments. Those requiring polypectomy or surgical resection experience short-term procedural recovery, potential complications (e.g., bleeding, perforation), and long-term surveillance obligations—impacting work productivity, travel, and healthcare engagement. Timely diagnosis via high-definition endoscopy with chromoendoscopy or narrow-band imaging, coupled with targeted biopsy and histopathologic classification, is essential to guide risk-stratified management and prevent unnecessary interventions or missed malignancy.

# 胃息肉治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用于：直径＜5mm、无异型增生、无症状的增生性/炎性息肉，随访观察为主。

• •内镜监测：胃镜复查（每1–3年），含病理活检：¥380–¥620/次
• •抑酸+黏膜保护：PPI（如艾司奥美拉唑）+瑞巴派特，3个月疗程：¥260–¥580
• •幽门螺杆菌根除（若阳性）：四联疗法（含铋剂）2周，药费+呼气试验复查：¥420–¥950

二、内镜下切除术（主流根治方案）

适用于：直径≥5mm、腺瘤性息肉、伴低级别上皮内瘤变者。

• •术前检查：血常规+凝血功能+心电图+幽门螺杆菌检测：¥320–¥480
• •内镜下高频电切（EMR）：单发≤10mm息肉，含麻醉、病理、术后用药：¥2,800–¥4,500
• •内镜黏膜下剥离（ESD）：≥15mm或疑似高级别瘤变，含精细剥离及病理分层评估：¥6,200–¥9,800

三、特殊复杂情况处理

• •多发息肉（≥5枚）或家族性腺瘤性息肉病（FAP）：需全胃镜精查+基因检测（MLH1/MSH2等）：¥4,500–¥12,000；长期随访管理年均费用约¥1,800–¥3,200
• •高级别瘤变或早期癌变：转外科评估，联合内镜+腹腔镜探查，总费用¥15,000–¥28,000

方案快速选择指南

✅ 预算有限/初筛发现小息肉：首选年度胃镜监测+PPI治疗（¥600内/年） ✅ 中青年/腺瘤性息肉：EMR切除（性价比最优，48小时内出院） ✅ 高危人群（家族史/多发/≥10mm）：直接ESD+分子病理（避免漏切与复发）